Download PDF
Dtsch Med Wochenschr 2013; 138(45): 2309-2312
DOI: 10.1055/s-0033-1349597
Aktuelle Diagnostik & Therapie | Review article
Gastroenterologie, Pharmakotherapie
© Georg Thieme Verlag KG Stuttgart · New York

Antidiarrhoika bei chronischer Diarrhoe

Antidiarrheal drugs for chronic diarrhea
B. Vohmann
1   Medizinische Klinik I, St. Marienkrankenhaus Ludwigshafen
,
J. C. Hoffmann
1   Medizinische Klinik I, St. Marienkrankenhaus Ludwigshafen
› Author Affiliations
Further Information

Publication History

17 April 2013

18 July 2013

Publication Date:
25 October 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Chronischer Diarrhoe können zahlreiche Ursachen zugrunde liegen, so dass eine geeignete Basisdiagnostik erforderlich ist. Wann immer möglich sollte entsprechend eine spezifische Therapie durchgeführt werden. Ist keine spezielle Therapie möglich, kann eine symptomatische Therapie eingeleitet werden, um dem massiven Elektrolyt- und Wasserverlust entgegenzuwirken und eine Besserung der Lebensqualität des Patienten zu erreichen. Zum Einsatz kommen insbesondere Loperamid, Colestyramin, Quellstoffe/Ballaststoffe, Probiotika, Anticholinerika und bei schweren Verläufen Opioide. Bei sachgemäßem Einsatz der o. g. Medikamente ist selbst eine Dauertherapie mit einem niedrigen Nebenwirkungspotential verbunden.

Abstract

Chronic diarrhea can be caused by multiple disease entities. Basic diagnostic tests are required in order to administer specific therapies whenever possible. If no specific treatment can be used, a symptomatic management should be initiated in order to prevent massive electrolyte- and water losses. Substances that can be used are loperamide, cholestyramine, bulking agents, probiotics, anticholinergic agents and in severe cases opioids. If used properly these agents can be prescribed longterm with an acceptable side effect profile.

Schlüsselwörter

Differenzialdiagnose - Gallensäureverlustsyndrom - Opioide - Megacolon

Keywords

differential diagnosis - bile acid malabsorption - opioids - megacolon
 

  • Literatur

  • 1 Abraham BP, Sellin JH. Drug-induced, factitious, & idiopathic diarrhoea. Best Pract Res Clin Gastroenterol 2012; 26: 633-648
    CrossrefPubMedGoogle Scholar
  • 2 Benson 3rd AB, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918-2926
    CrossrefPubMedGoogle Scholar
  • 3 Corbould A, Campbell J. Efficacy of octreotide but not long-acting somatostatin analogue for severe refractory diabetic diarrhoea. Diabet Med 2009; 26: 828-829
    CrossrefPubMedGoogle Scholar
  • 4 DiStefano PS, Brown OM. Biochemical correlates of morphine withdrawal. 2. Effects of clonidine. J Pharmacol Exp Ther 1985; 233: 339-344
    PubMedGoogle Scholar
  • 5 Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 463-468
    CrossrefPubMedGoogle Scholar
  • 6 Fedorak RN, Field M, Chang EB. Treatment of diabetic diarrhea with clonidine. Ann Intern Med 1985; 102: 197-199
    CrossrefPubMedGoogle Scholar
  • 7 Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116: 1464-1486
    CrossrefPubMedGoogle Scholar
  • 8 Hoffmann JC, Zeitz M. Small bowel disease in the elderly: diarrhoea and malabsorption. Best Pract Res Clin Gastroenterol 2002; 16: 17-36
    CrossrefPubMedGoogle Scholar
  • 9 Kaiser L, Surawicz CM. Infectious causes of chronic diarrhoea. Best Pract Res Clin Gastroenterol 2012; 26: 563-571
    CrossrefPubMedGoogle Scholar
  • 10 Li Z, Vaziri H. Treatment of chronic diarrhoea. Best Pract Res Clin Gastroenterol 2012; 26: 677-687
    CrossrefPubMedGoogle Scholar
  • 11 McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008; 14: 2650-2661
    CrossrefPubMedGoogle Scholar
  • 12 Meyer C, O'Neal DN, Connell W et al. Octreotide treatment of severe diabetic diarrhoea. Intern Med J 2003; 33: 617-618
    CrossrefPubMedGoogle Scholar
  • 13 Murray JA, Rubio-Tapia A. Diarrhoea due to small bowel diseases. Best Pract Res Clin Gastroenterol 2012; 26: 581-600
    CrossrefPubMedGoogle Scholar
  • 14 Nehra V, Camilleri M, Burton D et al. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol 2001; 96: 1494-1498
    CrossrefPubMedGoogle Scholar
  • 15 Parisi GC, Zilli M, Miani MP et al. High-fiber diet supplementation in patients with irritable bowel syndrome (IBS): a multicenter, randomized, open trial comparison between wheat bran diet and partially hydrolyzed guar gum (PHGG). Dig Dis Sci 2002; 47: 1697-1704
    CrossrefPubMedGoogle Scholar
  • 16 Roy SL, Scallan E, Beach MJ. The rate of acute gastrointestinal illness in developed countries. J Water Health 2006; 4 (Suppl. 02) 31-69
    CrossrefPubMedGoogle Scholar
  • 17 Schiller LR. Definitions, pathophysiology, and evaluation of chronic diarrhoea. Best Pract Res Clin Gastroenterol 2012; 26: 551-562
    CrossrefPubMedGoogle Scholar
  • 18 Wald A. Irritable bowel syndrome – diarrhoea. Best Pract Res Clin Gastroenterol 2012; 26: 573-580
    CrossrefPubMedGoogle Scholar
  • 19 Walley T, Milson D. Loperamide related toxic megacolon in Clostridium difficile colitis. Postgrad Med J 1990; 66: 582
    PubMedGoogle Scholar
  • 20 Walters JR, Tasleem AM, Omer OS et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009; 7: 1189-1194
    CrossrefPubMedGoogle Scholar
  • 21 Wedlake L, A'Hern R, Russell D et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2009; 30: 707-717
    CrossrefPubMedGoogle Scholar